Advertisement
U.S. markets open in 9 hours 25 minutes
Advertisement

Passage Bio, Inc. (PASG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
0.6311-0.0290 (-4.39%)
At close: 04:00PM EST
0.6734 +0.04 (+6.70%)
After hours: 07:25PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close0.6601
Open0.6700
Bid0.6260 x 1200
Ask0.7239 x 1200
Day's Range0.6311 - 0.7148
52 Week Range0.5750 - 1.9200
Volume161,829
Avg. Volume217,711
Market Cap34.597M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PASG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Passage Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/20/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

    PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise pric

  • GlobeNewswire

    Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

    On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025 PHILA

  • GlobeNewswire

    Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

    PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on